Psilocin’s next target: Tryptamine Therapeutics (ASX:TYP) takes aim at IBS

For many, Irritable Bowel Syndrome (IBS) remains a debilitating condition with few effective treatments.

However, Melbourne-based Tryptamine Therapeutics (ASX:TYP) has delivered a shot of optimism with interim results from its Phase 2a trial at Massachusetts General Hospital (MGH).

The study, assessing psilocybin’s active metabolite psilocin, could make TYP a frontrunner in a burgeoning market targeting the gut-brain axis.

Conducted in partnership with MGH – marking the first-ever clinical administration of psilocybin at the prestigious facility – the trial involves up to 10 IBS patients.

Early data is strong: 75% of the first cohort reported clinically meaningful reductions in both abdominal pain and gastrointestinal anxiety, two hallmarks of IBS.

For those in the sector, this news is more than a mild belly rub.

TYP’s therapeutic innovation, TRP-8803, offers several advantages over its oral predecessors, including precise dosing via IV infusion, rapid onset (within 20 minutes), and controlled treatment duration – critical for commercial scalability.

According to CEO Jason Carroll, the results reinforce the viability of TRP-8803:

“This interim analysis highlights that IBS is highly likely to be a viable indication for Tryp to pursue for commercialisation with TRP-8803 (IV-infused psilocin)”.

A Scalable Solution to a Global Problem

IBS affects 20% of Australians and 15% of Americans, making it a global health priority.

TYP’s innovative solution has the potential to alleviate not just the physical pain but also the anxiety and depression often intertwined with IBS symptoms.

Importantly, the gut-brain interplay underpins TYP’s scientific rationale, as psilocin interacts with serotonin receptors, crucial for both mood and gastrointestinal function.

The company is leveraging results from TRP-8802 (oral psilocybin) trials to inform its lead asset, TRP-8803.

Prior studies in Binge Eating Disorder and Fibromyalgia showed similar promise, with outcomes including an 80% reduction in binge-eating episodes and significant pain relief.

What’s Next?

While MGH continues dosing patients in the IBS trial, TYP is already incorporating the data into its proprietary platform. Carroll confirmed:

“Our work will commence to incorporate these interim results into our expanding proprietary dataset. This will, in turn, underpin the company’s future clinical trial pipeline”.

For a biopharmaceutical firm that only listed on the ASX relatively recently, TYP is punching well above its weight.

With neuroplasticity fast becoming the darling of mental health and pain therapeutics, TRP-8803 could emerge as a differentiated, commercially feasible solution.

With IBS costing healthcare systems billions annually in productivity losses and absenteeism, TYP’s psilocin-based therapy stands out as more than another psychedelic experiment.

It’s a potential game-changer – for patients, investors, and a company keen to prove psilocin’s worth beyond the headlines.

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.